SCHEMBL7941663

SCHEMBL7941663

Nc1ncccc1NCc1cccc(NC(=O)c2cc3ccccc3o2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.58
NPC1 O15118 13/20 0.56
RAB9A P51151 12/20 0.56
TP53 P04637 8/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
TSHR P16473 5/20 0.56
LMNA P02545 4/20 0.56
KDM4E B2RXH2 2/20 0.56
ALDH1A1 P00352 2/20 0.56
USP2 O75604 1/20 0.56
GAA P10253 1/20 0.56
HPGD P15428 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
HSD17B10 Q99714 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
SMN1; SMN2 Q16637 6/20 0.54
PKM P14618 4/20 0.54
NFKB1 P19838 1/20 0.54
NFKB2 Q00653 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7940967 0.89 BACE1 (0.57) BACE1NPC1RAB9ATP53MEN1
SCHEMBL7940374 0.89 RAB9A (0.58) BACE1NPC1RAB9ATP53MEN1
SCHEMBL7941949 0.87 NPC1 (0.55) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL7932672 0.86 BACE1 (0.62) BACE1NPC1RAB9ATP53MEN1
SCHEMBL12301465 0.85 NPC1 (0.53) NPC1RAB9ATP53MEN1KMT2A
SCHEMBL12301760 0.83 BACE1 (0.59) BACE1NPC1RAB9ATP53MEN1
SCHEMBL7944660 0.83 BACE1 (0.62) BACE1NPC1RAB9ALMNAALDH1A1
SCHEMBL7944676 0.83 BACE1 (0.57) BACE1NPC1RAB9ATP53MEN1
SCHEMBL7942432 0.82 BACE1 (0.69) BACE1SIRT2SIRT1SIRT3
SCHEMBL7933261 0.81 BACE1 (0.62) BACE1NPC1RAB9ATP53MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-29 US disclosed
WO-2010047372-A1 2-AMINOPYRIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVE BOTH HAVING BACE1-INHIBITING ACTIVITY 塩野義製薬株式会社 (JP) 2010-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237576-A1 2-AMINOPYRIMIDIN-4-ONE AND 2-AMINOPYRIDINE DERIVATIVES BOTH HAVING BACE1-INHIBITING ACTIVITY BACE1, APP, BACE2 BACE1 1/4885NPC1 431/4885RAB9A 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.